Vascular endothelial growth factor inhibition for proliferative diabetic retinopathy: Et tu, Brute?

Acta Ophthalmol. 2017 Dec;95(8):757-758. doi: 10.1111/aos.13562.

Author

Jakob Grauslund^{1

2}

Affiliations

¹ Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
² Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.

PMID: 29220127
DOI: 10.1111/aos.13562

No abstract available

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Diabetic Retinopathy / drug therapy*
Diabetic Retinopathy / metabolism
Dose-Response Relationship, Drug
Drug Administration Schedule
Follow-Up Studies
Humans
Intravitreal Injections
Randomized Controlled Trials as Topic
Ranibizumab / administration & dosage*
Time Factors
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Vascular Endothelial Growth Factor A / metabolism
Vitreous Body / metabolism*

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Ranibizumab